BASEL, Switzerland, May 25, 2016 /PRNewswire/ --
- Eversense is the first implantable continuous glucose monitoring (CGM) sensor to measure glucose values for up to 90 days without the need to change the sensor every week or to carry an additional receiving device.
- The system will allow people with diabetes to manage their disease with more flexibility, confidence and discretion.
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced an exclusive distribution agreement with Senseonics Holding Inc. for the new Eversense® CGM System to be marketed in Italy, Germany and the Netherlands. The system is designed to continually monitor glucose levels for up to 90 days, compared to 7 or up to 14 days for non-implantable CGM systems currently available in the market. The sensor is implanted underneath the skin on the upper arm and communicates with a rechargeable and removable smart transmitter that is worn on the upper arm. Glucose data and trends are available on the Eversense mobile app. In addition, the smart transmitter sets off an alert when glucose levels become too high or too low. These features provide people with diabetes with important real-time insights on glucose levels and trends throughout the day and actionable information to flexibly and discreetly manage their condition. Under the terms of the agreement, the CE-marked CGM system will be introduced in the first markets Italy, Germany, and the Netherlands shortly. Both companies will jointly make the Eversense system available to people with diabetes via clinics and medical practices that have been trained on the system.
"We are excited to bring this advancement in diabetes therapy to our customers. It is an excellent fit and addition to our Accu-Chek® portfolio," states Marcel Gmuender, Global Head of Roche Diabetes Care. "With the launch of our Accu-Chek Insight CGM system at the end of this year, we are reinforcing our commitment to provide people with diabetes broad access to innovation with two CGM solutions that will help meet different patient needs and provide true relief."
Continuous glucose monitoring is considered the most significant breakthrough in diabetes management in the past years. It can provide people with diabetes on insulin therapy with valuable additional information to help keep track of an optimal glycemic control and can also contribute to a risk reduction of both severe hypo- and hyperglycemia. CGM devices relay frequent readings of glucose levels from a small sensor inserted under the skin measuring the glucose in the interstitial fluid. The benefit of CGM is that it provides useful real-time insights into patterns and trends in glucose levels throughout the day. CGM devices can be programmed to alert the user when glucose levels are too low or too high.
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' first generation continuous glucose monitoring (CGM) system, Eversense®, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels.
For more information on Senseonics, please visit http://www.senseonics.com.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 40 years, the Accu-Chek brand has been dedicated to enabling people with diabetes to live life as normally and actively as possible as well as to empowering healthcare professionals to manage their patients' condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management, spanning from blood glucose monitoring through information management to insulin delivery. The Accu-Chek brand encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs - contributing to an improved medical outcome.
For more information please visit http://www.accu-chek.com
All trademarks used or mentioned in this release are protected by law.
References:: 1 Clarke SF and Foster JR.. Br J Biomed Sci. 2012;(3)2:83-93
For more information, please contact:
Roche Diabetes Care
SOURCE Roche Diabetes Care